Author: Bret Jensen, Biotech Gems

In a market that seems increasingly vulnerable to a significant pullback, they could be good pickups in any decline…

One has over $3 billion in net cash (which is more than 25% of its overall market cap), while the other is worth accumulating in any overall dip in the market…

They’re giving off strong signals that they could be acquired, giving their shareholders massive instantaneous returns…

They’re attractive but speculative names I hold in my portfolio…